Loss of heterozygosity reveals non-VHL allelic loss in hemangioblastomas at 22q13.

[1]  A. Vortmeyer,et al.  Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. , 2003, Cancer research.

[2]  M. Hoang,et al.  Inhibin Alpha Distinguishes Hemangioblastoma From Clear Cell Renal Cell Carcinoma , 2003, The American journal of surgical pathology.

[3]  J. Prchal,et al.  Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. , 2003, American journal of human genetics.

[4]  J. Gnarra,et al.  Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. , 2003, Cancer cell.

[5]  G. Reifenberger,et al.  Genetic Alterations Commonly Found in Diffusely Infiltrating Cerebral Gliomas Are Rare or Absent in Pleomorphic Xanthoastrocytomas , 2002, Journal of neuropathology and experimental neurology.

[6]  A. Vortmeyer,et al.  New Insights into the Genetics of Familial Chromaffin Cell Tumors , 2002, Annals of the New York Academy of Sciences.

[7]  J. Biegel,et al.  Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System: Report on Workshop , 2002, Journal of pediatric hematology/oncology.

[8]  I. Nishimoto,et al.  Distinct regions of loss of heterozygosity on 22q in different sites of head and neck squamous cell carcinomas. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[9]  M. Alonso,et al.  Loss of chromosome 22 and absence of NF2 gene mutation in a case of multiple meningiomas. , 2002, Human pathology.

[10]  J. Tonn,et al.  Loss of heterozygosity on chromosome 22 in human ependymomas , 2002, Acta Neuropathologica.

[11]  A. Wild,et al.  A novel insulinoma tumor suppressor gene locus on chromosome 22q with potential prognostic implications. , 2001, The Journal of clinical endocrinology and metabolism.

[12]  E. Zwarthoff,et al.  Truncated NF2 proteins are not detected in meningiomas and schwannomas , 2001, Neuropathology : official journal of the Japanese Society of Neuropathology.

[13]  A. von Deimling,et al.  Indications for a tumor suppressor gene at 22q11 involved in the pathogenesis of ependymal tumors and distinct from hSNF5/INI1 , 2001, Acta Neuropathologica.

[14]  P. Wesseling,et al.  Characteristic Chromosomal Aberrations in Sporadic Cerebellar Hemangioblastomas Revealed by Comparative Genomic Hybridization , 2001, Journal of Neuro-Oncology.

[15]  A. von Deimling,et al.  Mutational analysis of INI1 in sporadic human brain tumors , 2001, Acta Neuropathologica.

[16]  Hyun B Choi,et al.  Erythropoietin and Erythropoietin Receptors in Human CNS Neurons, Astrocytes, Microglia, and Oligodendrocytes Grown in Culture , 2001, Journal of neuropathology and experimental neurology.

[17]  R. Sciot,et al.  The neurofibromatosis type 2 gene is mutated in perineurial cell tumors: a molecular genetic study of eight cases. , 2001, The American journal of pathology.

[18]  W. Kaelin,et al.  The von Hippel-Lindau tumor suppressor gene. , 2001, Experimental cell research.

[19]  W. Brück,et al.  Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain , 2001, Acta Neuropathologica.

[20]  C. Eng,et al.  Differential genetic alterations in von Hippel-Lindau syndrome-associated and sporadic pheochromocytomas. , 2000, The Journal of clinical endocrinology and metabolism.

[21]  Till Acker,et al.  Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function , 2000, Oncogene.

[22]  A. Vortmeyer,et al.  Somatic von Hippel-Lindau gene mutations detected in sporadic endolymphatic sac tumors. , 2000, Cancer research.

[23]  K. Plate,et al.  VEGF in Brain Tumors , 2000, Journal of Neuro-Oncology.

[24]  T. Hulsebos,et al.  A region of common deletion in 22q13.3 in human glioma associated with astrocytoma progression , 2000, International journal of cancer.

[25]  G. Perilongo,et al.  Somatic mosaicism in von Hippel‐Lindau disease , 2000, Human mutation.

[26]  K. Hoang-Xuan,et al.  Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. , 1999, Human molecular genetics.

[27]  A. Gregor,et al.  Angiogenic histogenesis of stromal cells in hemangioblastoma: ultrastructural and immunohistochemical study. , 1999, Ultrastructural pathology.

[28]  S. Richard,et al.  [Neuro-endocrine tumors and von Hippel-Lindau disease. 3 cases]. , 1999, Presse medicale.

[29]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[30]  A. Vortmeyer,et al.  VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma. , 1999, Archives of ophthalmology.

[31]  J. Krupiński,et al.  Vascular endothelial growth factor and its receptor, KDR, in human brain tissue after ischemic stroke. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[32]  J. Rosenstein,et al.  VEGF mRNA and Its Receptorflt-1Are Expressed in Reactive Astrocytes Following Neural Grafting and Tumor Cell Implantation in the Adult CNS , 1998, Experimental Neurology.

[33]  K. Plate,et al.  Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function , 1998 .

[34]  M. Golubić,et al.  Immunoblotting analysis of schwannomin/merlin in human schwannomas. , 1998, The American journal of otology.

[35]  Olivier Delattre,et al.  Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer , 1998, Nature.

[36]  K. Plate,et al.  Up-Regulation of Vascular Endothelial Growth Factor in Stromal Cells of Hemangioblastomas Is Correlated with Up-Regulation of the Transcription Factor HRF/HIF-2α , 1998 .

[37]  S. Curley,et al.  Surgical decision-making affected by clinical and genetic screening of a novel kindred with von Hippel-Lindau disease and pancreatic islet cell tumors. , 1998, Annals of surgery.

[38]  W. Linehan,et al.  Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. , 1998, Cancer research.

[39]  M. Emmert-Buck,et al.  von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. , 1997, Human pathology.

[40]  W. Poon,et al.  Molecular genetic analysis of the von Hippel-Lindau disease tumor suppressor gene in familial and sporadic cerebellar hemangioblastomas. , 1997, American journal of clinical pathology.

[41]  S. Pulst,et al.  Immunohistochemical Detection of Schwannomin and Neurofibromin in Vestibular Schwannomas, Ependymomas and Meningiomas , 1997, Journal of neuropathology and experimental neurology.

[42]  Satoshi O. Suzuki,et al.  Expression of neurofibromatosis 2 protein in human brain tumors: an immunohistochemical study , 1997, Acta Neuropathologica.

[43]  S. Masuda,et al.  Insulin-like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes , 1997, Brain Research.

[44]  A. Paetau,et al.  Different expression of adhesion molecules on stromal cells and endothelial cells of capillary hemangioblastoma , 1996, Acta Neuropathologica.

[45]  K. Plate,et al.  Pathology, genetics and cell biology of hemangioblastomas. , 1996, Histology and histopathology.

[46]  J. Bruce,et al.  Frequent type 2 neurofibromatosis gene transcript mutations in sporadic intramedullary spinal cord ependymomas. , 1996, Neurosurgery.

[47]  G. Reifenberger,et al.  MUTATION OF THE VON HIPPEL–LINDAU TUMOUR SUPPRESSOR GENE IN CAPILLARY HAEMANGIOBLASTOMAS OF THE CENTRAL NERVOUS SYSTEM , 1996, The Journal of pathology.

[48]  F. Vitelli,et al.  Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas , 1996, Human Genetics.

[49]  M. Gassmann,et al.  Erythropoietin Gene Expression in Human, Monkey and Murine Brain , 1996, The European journal of neuroscience.

[50]  K. Alitalo,et al.  Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. , 1996, The American journal of pathology.

[51]  W. Poon,et al.  Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors. , 1995, Neurosurgery.

[52]  J. Minna,et al.  Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. , 1995, Cancer research.

[53]  K. Plate,et al.  Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. , 1995, Cancer research.

[54]  T. Shuin,et al.  Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. , 1994, Cancer research.

[55]  K. Yamagishi,et al.  A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. , 1994, The Journal of biological chemistry.

[56]  H. Nagase,et al.  Alternative splicing of the NF2 gene and its mutation analysis of breast and colorectal cancers. , 1994, Human molecular genetics.

[57]  J. Gusella,et al.  Exon scanning for mutation of the NF2 gene in schwannomas. , 1994, Human molecular genetics.

[58]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[59]  J. Rey,et al.  Involvement of 22q12 in a neurofibrosarcoma in neurofibromatosis type 1. , 1993, Cancer genetics and cytogenetics.

[60]  J. Rey,et al.  Abnormalities of chromosome 22 in human brain tumors determined by combined cytogenetic and molecular genetic approaches. , 1993, Cancer genetics and cytogenetics.

[61]  Xu Qw,et al.  [Hemangioblastoma of the central nervous system]. , 1989, Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry.

[62]  Y. Nakamura,et al.  Specific genetic change in tumors associated with von Hippel-Lindau disease. , 1989, Journal of the National Cancer Institute.

[63]  L. True,et al.  Immunohistochemistry of Capillary Hemangioblastoma: Immunoperoxidase‐Labeled Antibody Staining Resolves the Differential Diagnosis with Metastatic Renal Cell Carcinoma, But Does Not Explain the Histogenesis of the Capillary Hemangioblastoma , 1989, The American journal of surgical pathology.

[64]  W. Paulus,et al.  Histogenesis of stromal cells in cerebellar hemangioblastomas. An immunohistochemical study. , 1989, The American journal of pathology.

[65]  A. Tanimura,et al.  Hemangioblastoma of the central nervous system: nature of the stromal cells as studied by the immunoperoxidase technique. , 1984, Human pathology.

[66]  A. Chaudhry,et al.  Ultrastructure of cerebellar hemangioblastoma , 1978, Cancer.

[67]  K. Tory,et al.  Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours , 2004, Human Genetics.

[68]  P. Mckeever,et al.  Selective localization of γ-enolase in stromal cells of cerebellar hemangioblastomas , 2004, Acta Neuropathologica.

[69]  E. Oldfield,et al.  The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. , 2003, Journal of neurosurgery.

[70]  J. Rey,et al.  Chromosomal abnormalities in pituitary adenomas. , 2001, Cancer genetics and cytogenetics.

[71]  M. Beckner.  Factors promoting tumor angiogenesis. , 1999, Cancer investigation.

[72]  G. Thomas,et al.  Germline mutation profile of the VHL gene in von Hippel‐Lindau disease and in sporadic hemangioblastoma , 1998, Human mutation.

[73]  J. Rey,et al.  Cytogenetics and molecular genetics of nervous system tumors. , 1992, Oncology research.

[74]  P. Gallagher,et al.  Haemangioblastoma , 2004, Acta Neuropathologica.